Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very nice presentation, happy with the news
Magnus
Hope you do not mind, but I used your information for comments on yahoo's finance
Long UOIP,
~Magnus
Good Morning UOIP Longs
Looking forward to more news on the success of Chanbond and UOIP.
Long UOIP,
~Magnus
Broke, Let me know what's missing and I will she what could have happened. There are backups which I looked at and I am not sure what could be missing.
Long UOIP,
~Magnus
The internet is a crazy place, but I have been emailing small investment website and included a link to your article. Doing my part to keep the pressure on.
Long UOIP,
Magnus
CommScope has coconuts for balls.
In the mists of this patent infringement with Chanbond/UOIP's DOCSIS they have the nerve to roll out a product using DOCSIS.
https://www.digitaltveurope.com/2019/06/07/commscope-highlights-low-latency-docsis-and-soft-fdd-at-anga-com/
That's fine, just adds more to the penalties
Long UOIP,
~Magnus
We are finished talking about the origination of the patents, that is irrelevant and so is the mental capacity of these investors. They most important thing here is that Arris/CommScope are going to make every single one of us as rich as king$ LOL!!!!!
Long UOIP,
~Magnus
Why do you bother asking questions that you already know the answer to and you also know that we know the answer. I guess you just like to use the patent troll word.
Long UOIP,
~Magnus
How long could they expect to monetize the patents? Would the cost justify the expense. Or would they buy the patents just to make this go away.
Our 3 patents were filed as follows:
This application is a divisional of application Ser. No. 09/749,258, filed on Dec. 27, 2000 now U.S. Pat. No. 7,346,918
This application is a divisional of application Ser. No. 12/068,102, filed on Feb. 1, 2008, now U.S. Pat. No. 7,941,822, which is a divisional of application Ser. No. 09/749,258, filed on Dec. 27, 2000, now U.S. Pat. No. 7,346,918.
This application is a continuation of application Ser. No. 12/564,663 filed on Sep. 22, 2009, which is a divisional of application Ser. No. 12/068,102, filed on Feb. 1, 2008, now U.S. Pat. No. 7,941,822, which is a divisional of application Ser. No. 09/749,258,
Plant patents and utility patents last up to 20 years from the date of application, while patents for designs last up to 14 years from the date of application. Plant and utility patents granted prior to 1995 last 17 years. When your patent expires, you no longer have exclusive rights to manufacture and sell the product.
What type of patent do we hold and how long till they expire?
Long UOIP,
Magnus
Reminds me.... when I was reading the Rainmaker and the insurance company sent that letter “...are you stupid...” I couldn’t help but wonder did the inventors of Channel Bonding get a similar response when they confronted the cable companies?
I enjoy all of John Grisham’s books
Long UOIP,
Magnus
Runaway Jury where they went after big tobacco?
Or the Rainmaker and the scumbag insurance company?
Both are great books and have some likeness to the 13 + cable modem manufacturers
Long UOIP,
Magnus
Given the choice of buying the patents from us or recalling/destroying all 3.1 DOCIS modems, I would hope they are smart enough to choose buying the patents.
Keep in mind that the recalling/destroying bit is a page from their book, and not my suggestion.
Long UOIP,
~Magnus
https://www.commscope.com/NewsCenter/PressReleases/German-Patent-Court-Finds-Comlabs-Repeaters-Infringe-CommScope-Patents/
Something like that would definitely put CommScope out of business and I would be loading up on UPS stock LOL!!!
Long UOIP,
~Magnus
In a recent CommScope case from 2/14/2019, CommScope has the option to recall and destroy infringing products. Karma would be a real bitch if that were the decision handed down to them in our case regarding their patent infringement. Would they so proudly post that on their website?
https://www.commscope.com/NewsCenter/PressReleases/German-Patent-Court-Finds-Comlabs-Repeaters-Infringe-CommScope-Patents/
"In two decisions, a German patent court has found that Comlab has infringed mobile radio transmission patents owned by Andrew Wireless Systems, an affiliate of CommScope, a global leader in infrastructure solutions for communications networks."
"...The decisions, issued in Action Nos. 4c O 75/17 and 4c O 76/17, allow CommScope to preliminarily enforce—which provides CommScope the option to recall and destroy the infringing products as well as, under one of the decisions, get a preliminary injunction against further infringement. Two additional utility model enforcement actions are pending against Comlab’s repeater systems RUD19-5 in the District Court of Düsseldorf (Action Nos. 4c O 8/2018 and 4c O 26/18)..."
Long UOIP,
~Magnus
Then you better watch out, you have been spreading tons of fake news on this board alone.
Long UOIP,
~Magnus
My guess is that everyone is trying to cover themselves. Take a look at the short report and notice the massive increase on My 21, 2019. On 5/21/19 this opened at $0.0001 and closed at $0.0003
Just maybe the MM's are trying to walk this back down to $0.0003 to regain their loses???
~Magnus
P.S. https://www.otcshortreport.com/company/LAHO
OTCShort Report
https://www.otcshortreport.com/company/LAHO
Jun 05
660,363,907 Volume
381,376,295 Short Volume
57.75 % of Vol Shorted
Jun 04
677,937,532 Volume
321,313,464 Short Volume
47.40 % of Vol Shorted
Jun 03
315,547,375 Volume
241,059,195 Short Volume
76.39 % of Vol Shorted
~Magnus
Considering the sizes of the BID & ASK this looks like the MM's are sliding shares back and forth and playing games
~Magnus
Great job AJ!!!
My hat is off to you guys that can write articles like that. You are a true asset to the iHub UOIP Club!!!!
Long UOIP,
~Magnus
CommScope could be preparing to payout to Chanbond $UOIP
CommScope's 10-Q March 31, 2019 that was not in their 10-Q a year ago.
Litigation and Regulatory Risks
We may incur costs and may not be successful in protecting our intellectual property and in defending claims that we are infringing on the intellectual property of others.
We may encounter difficulties and significant costs in protecting our intellectual property rights or obtaining rights to additional intellectual property to permit us to continue or expand our business. Other companies, including some of our largest competitors, hold intellectual property rights in our industry and the intellectual property rights of others could inhibit our ability to introduce new products unless we secure necessary licenses on commercially reasonable terms.
In the past, we have initiated litigation in order to enforce patents issued or licensed to us or to determine the scope and/or validity of a third party’s patent or other proprietary rights, and we may initiate similar litigation in the future. We also have been and may in the future be subject to lawsuits by third parties seeking to enforce their own intellectual property rights, including against certain of the products or intellectual property that we have acquired through acquisitions. Any such litigation, regardless of outcome, could be costly and could subject us to significant liabilities or require us to cease using proprietary third-party technology. In addition, the payment of any damages or any necessary licensing fees or indemnification costs associated with a patent infringement claim could be material and could also materially adversely affect our operating results. Such litigation can also be a significant distraction to management.
CommScope 10-Q 3/31/2019
http://ir.commscope.com/node/12811/html
CommScope 10-Q 3/31/2018
http://ir.commscope.com/node/12021/html
I agree with Allinfun and it may only take bringing attention to Commscopes very own 10-Q
Long UOIP,
~Magnus
Exactly... A quick google search of "Commscope" and "Patent Infringement" will show you that Commscope is no stranger to the courtroom. I am sure they know fighting Chanbond's patents will cut deep into their pockets. They just paid $7.5 Billion for Arris and now they may pay just as much for the Chanbond patents
Long UOIP,
~Magnus
Significant Patent Win for TQ Delta
AUSTIN, Texas--(BUSINESS WIRE)--May 29, 2019--
TQ Delta LLC, a technology development and licensing firm, secured another favorable judgment last week when a Delaware federal jury found that 2Wire Inc. infringed three of TQ Delta’s patents related to Digital Subscriber Line (“DSL”) technology. 2Wire is a subsidiary of ARRIS Solutions, which was recently acquired by CommScope Inc.
Looks like Commscope is not just dealing with the patent infringement of UOIP/Chanbond
Long UOIP,
~Magnus
Annual Meeting of Stockholders June 21, 2019
Commscope
The Annual Meeting
Date and Time:
Friday, June 21, 2019
1:00 pm, local time
Place:
JPMorgan Chase
383 Madison Avenue
New York, NY 10179
I would love to be a fly on the wall at that meeting since " the payment of any damages or any necessary licensing fees or indemnification costs associated with a patent infringement claim could be material and could also materially adversely affect our operating results. Such litigation can also be a significant distraction to management. "
Long UOIP,
~Magnus
It's a safe assumption considering this comment "including against certain of the products or intellectual property that we have acquired through acquisitions." Sure sounds like Arris and our IP
Long UOIP,
~Magnus
Let's hope it's just the MM's walking this down because they expect a surge upwards.
Long BYOC,
~Magnus
Found something in CommScope's 10-Q March 31, 2019 that was not in their 10-Q a year ago.
Litigation and Regulatory Risks
We may incur costs and may not be successful in protecting our intellectual property and in defending claims that we are infringing on the intellectual property of others.
We may encounter difficulties and significant costs in protecting our intellectual property rights or obtaining rights to additional intellectual property to permit us to continue or expand our business. Other companies, including some of our largest competitors, hold intellectual property rights in our industry and the intellectual property rights of others could inhibit our ability to introduce new products unless we secure necessary licenses on commercially reasonable terms.
In the past, we have initiated litigation in order to enforce patents issued or licensed to us or to determine the scope and/or validity of a third party’s patent or other proprietary rights, and we may initiate similar litigation in the future. We also have been and may in the future be subject to lawsuits by third parties seeking to enforce their own intellectual property rights, including against certain of the products or intellectual property that we have acquired through acquisitions. Any such litigation, regardless of outcome, could be costly and could subject us to significant liabilities or require us to cease using proprietary third-party technology. In addition, the payment of any damages or any necessary licensing fees or indemnification costs associated with a patent infringement claim could be material and could also materially adversely affect our operating results. Such litigation can also be a significant distraction to management.
CommScope 10-Q 3/31/2019
http://ir.commscope.com/node/12811/html
CommScope 10-Q 3/31/2018
http://ir.commscope.com/node/12021/html
Long UOIP,
~Magnus
These prices are hard to resist.
Long IGMB,
~Magnus
Thank you Toanoman, I will get that information into the iBox
Long UOIP,
~Magnus
Thank you for the clarification
Long UOIP,
Magnus
What stage of the Chanbond vs Cisco appeal are we in. According to this chart?
http://www.cafc.uscourts.gov/sites/default/files/rules-of-practice/notices/Life_of_an_Appeal_Narrative_and_flowchart.pdf
Long UOIP,
Magnus
From the beginning of your posting here have tried to conflate legitimate NPE's with Patent Trolls. They are not one in the same. Legitimate NPE's such as Chanbond serve a much needed function in our patent system keeping big tech companies from running roughshod over small underfunded patent owners and the fidelity of the patent system in general. Even Director Iancu, the current head of the USPTO, has made similar statements.
The term "Patent Troll" is a pejorative term coined by big tech companies and used by their lawyers, lobbyist, and bought and paid for politicians in order to cast all NPE's in the negative light of the "troll". They have been highly successful in their brain washing of America. But thanks to Iancu, the new sheriff in town, a new day has come.
Legitimate NPEs such as Chanbond employ a rigorous due diligence process to ensure that the patents they license are of good quality and highly likely to be upheld as valid by the courts and by patent office trial boards. Just as companies that manufacture products do, a legitimate licensing firm generally will resort to litigation to enforce its valid patents only after protracted good-faith negotiations with potential licensees have proven unsuccessful. They do not use the threat of litigation to seek nuisance settlements, nor do they threaten litigation against startup companies, product retailers, or retail consumers unless they directly compete with the licensor.
Patent trolls, on the other hand, often use low-quality or over broad patent claims to threaten litigation against hundreds of small businesses each year, even retail establishments such as coffee shops and hotels. They claim these businesses are infringing their patents simply by doing something as innocuous as scanning a document to email or offering WiFi access to customers. They then demand settlements of a few thousand dollars or threaten the business with an infringement suit that can cost literally millions of dollars to defend against.
These suits are known as strike suits—i.e., suits filed to extort nuisance settlements that are less than the cost of litigation—and are unfortunately nothing new in American courts. Similar suits are also filed every year in the personal injury, product liability, and shareholder rights arenas. In fact, personal injury and product liability suits outnumber patent suits by 10 to 1 every year. And given all the stories of ambulance-chasing lawyers and faked whiplash injuries, not to mention of people carrying cockroaches into fast-food joints and crying foul, it’s likely there are many times more abusive personal injury and product liability suits than abusive patent suits each year.
Thank you "choo choo trader"
Long UOIP,
~Magnus
Entered into a definitive business purchase agreement with ISSUES & ANSWERS NETWORK, Inc. and also closed the acquisition of PathUX, LLC. all in the same day 5/31/2019
Great way to start the month of June.
Long BYOC,
~Magnus
Some nice volume so far today:
2.97M as of 12:07 PM ET
$0.0073 +0.0012 (19.67%)
Some good news regarding the purchase agreement with Issues & Answers, Inc and the conference this week. Things are heating up
~Magnus
In 9 years iGambit had 29 news releases, therefore I am not alarmed that we haven't heard anything since August. I have been looking a similar stock $ALRT They offer FDA approved monitoring for diabetics. Both companies seem light on news and maybe because releasing soft news is just that, I will wait for confirmed good news. Below is a collection of releases.
Long IGMB,
~Magnus
August 23, 2018
August 9, 2018
June 19, 2018
May 8, 2018
April 24, 2018
November 2, 2017
October 9, 2017
August 23, 2017
August 17, 2017
July 26, 2017
July 5, 2017
June 14, 2017
May 8, 2017
April 07, 2017
Feb 15, 2017
Aug 26, 2016
Nov 10, 2015
Nov 11, 2015
May 19, 2015
May 13, 2015
April 3, 2012
Nov 17, 2011
Aug 17, 2011
July 19, 2011
Oct 22, 2009
July 12, 2009
==============================================================
iGambit announces partnership with Device Distributors, LLC, to expand HealthDatix® business into South and Central America.
August 23, 2018
SMITHTOWN, N.Y., August 23, 2018 (Globe Newswire) iGambit, Inc. (OTCBB: IGMB) is pleased to announce the company has signed an exclusive contract with Device Distributors, LLC, to expand its health monitoring and reporting system into Brazil, Argentina, and throughout South and Central America.
Device Distributors will represent iGambit subsidiary HealthDatix in the territory to facilitate the introduction of cloud data and trend data tracking, reporting, and analysis systems supported by HealthDatix’s wearable medical monitor, the BioDatix Health Band.
The BioDatix Health Band offers round-the-clock monitoring, passively collecting data on heart rate, blood pressure, blood oxygen, sleep, and steps/distance/calories, without affecting the patient’s routine. The device delivers accurate, real-time syncing of data to the HealthDatix platform for use by the client’s Care Team of Professionals, Caregivers, Physicians and their staffs, and is also designed to reduce the time from a BioDatix Health Band wearer’s medical incident to the application of often lifesaving treatments.
BioDatix Health Band transmits data to an FDA certified back-end application, to produce trend reports and alerts. Identified, “out of limit” or “unusual” baselines, can be reported by HealthDatix to the client’s Care Team. The Care Team professionals can receive alerts and send messages to any or all of the Wearer, Caregiver, Physicians, and Physicians’ staff to facilitate better user engagement in managing their overall health.
Our new enhanced health monitoring Health Band offers strategic synergies in multiple markets, e.g. health care management, chronic health conditions, fitness, reducing costs in employee wellness programs and self-insured companies, private self-monitoring, and importantly the continuous real time monitoring of an employee’s health who performs work which has the potential for a major disaster e.g. train conductors, airplane pilots, truck drivers, etc.
The global wearable medical devices market size was valued at USD 3.9 billion in 2014 and is expected to grow with a compound annual growth rate (CAGR) of 28% over the forecast period. Increasing demand for technologically advanced wearable medical devices, rising awareness regarding physical fitness, advent of new smartphone-linked healthcare applications, and growing demand for wireless connectivity in the healthcare industry are the key factors propelling the overall industry.
John Salerno, Chairman of iGambit stated: This partnership is an important step that will expand the market reach of HealthDatix, and create additional value for our customers and our stockholders. Device Distributors will provide the infrastructure to address the particular needs of institutional, legal, and logistic challenges in Brazil, Argentina, and throughout South and Central America.
About HealthDatix
The achievement of longer healthy lives for the population at large is our mission. Within any population there are some that are apparently healthy and some that are at risk. Consistent with our mission, we aggregate data and deliver accurate Information to a care giver who must make vital decisions on a course of treatment for those at risk. Just as importantly however, is that the health data we collect from the apparently healthy group is compiled into historical data reports available to an attending physician during a client’s office visit or telephone conference. The Caregiver for both the “at risk” and “apparently healthy” populations will no longer only have available a snapshot of health monitoring readings during an office visit which can be misleading at best but also a patients’ vital signs over the course of a desired period of time.
We are also helping to shape the future of our nation’s health care system with robust leveraging of technology that enhances our ability to deliver value based healthcare to all populations without employing additional staff or additional burdens on the Caregivers. Our proprietary data analytics management facilitates the conducting of, and fully utilizing, the new opportunities inherent in the Wellness Visit program. For more information regarding the Wellness Visits and 24/7/365 monitoring of clients with chronic conditions, please visit www.healthdatix.com
About Device Distributors, LLC
Device Distributors brings new technologies and data systems to business and institutional customers in Brazil, Argentina and throughout South and Central America. The company buys, brokers, and provides logistics, customs, and licensing support to enable clients to take advantage of cloud innovations, revolutionary medical devices, and consumer electronics that promote health and fitness. For more information, please visit www.devicedistributors.com.
iGambit (OTCBB: IGMB) is a fully reporting publicly-held company. For more information, please visit www.igambit.com. Information on our web site does not comprise a part of this press release.
Safe Harbor:
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intends," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, including but not limited to, economic conditions, dependence on management, dilution to shareholders, lack of capital changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth, demand for products and services of the Company, newly developing technologies, its ability to compete, conflicts of interest related to party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition, and the ability of the Company to obtain additional financing. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
Contact:
Jerry Robinson
727-226-2939
info@HealthDatix.com
==============================================================
iGambit Inc. announces innovative BioDatix Health Band Launch September 2018.
August 9, 2018
SMITHTOWN, N.Y., August 9, 2018 (Globe Newswire) iGambit, Inc. (OTCQB: IGMB) is pleased to announce our first pilot launch on our much awaited BioDatix Health Band.
HealthDatix will begin shipping our BioDatix Health Bands this month to a select group of clients’, whose, Care Team of professionals will embark on a September 2018 pilot program.
Over the past 18 months, HealthDatix focus has been on the software development on the new BioDatix Health Band, Android and iOS applications. The BioDatix Health Band will provide the ability to passively collect a wearers Heart Rate, Blood Oxygen, Blood Pressure, Sleep and Steps/Distance/Calories.
The data is then transmitted to our FDA approved back-end application producing trend reports and alerts. Identified “out of limit” or “unusal” baselines, can then be managed by HealthDatix or our clients’ “Care Team” of professionals. The Care Team professionals can receive alerts and send messages to, any or all of the Wearer, Caregiver, Physicians and Physicians’ staff to facilitate better user engagement in managing their overall health.
This new product offering offers strategic synergies in multiple markets, healthcare, fitness, and employee wellness programs.
John Salerno, CEO of iGambit stated: “The ability of our product and services to seamlessly integrate day-to-day, health-related activities into an application-health-based module is a game-changer in the healthcare market.”
*The global wearable market has a potential to reach $32.9 billion by 2020, registering a CAGR of 67.6% during 2014 - 2020, according to new research published by Allied Market Research. Increasing demand for technologically advanced wearable medical devices, rising awareness regarding physical fitness, advent of new smartphone-linked healthcare applications, and growing demand for wireless connectivity in the healthcare industry are the key factors propelling the overall industry.
https://www.alliedmarketresearch.com/press-release/smartwatch-market-is-expected-to-reach-32-9-billion-by-2020-allied-market-research.html
About HealthDatix
Healthy, Longer Lives, that’s our mission. Within the population of any group or organization there are people who are healthy and those that are at risk. Our mission is to aggregate their data and deliver accurate reporting necessary to make vital decisions on a course of treatment or education for those at risk. We empower you with the data needed to negotiate future health costs. We’re helping to shape the future of our nation’s health care system, with robust leveraging of technology that delivers value-based healthcare and payment without extra staff or additional efforts on the part of the caregiver. Our proprietary data analytics management uncovers new opportunities for health wellness visits and 24/7/365 monitoring of people with chronic conditions. For more information, please visit www.healthdatix.com.
iGambit (OTCQB: IGMB) is a fully reporting publicly-held company. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release.
==============================================================
Winpoint Health LLC and iGambit Inc. sign Letter of Intent for iGambit Inc. to acquire Winpoint Health LLC
June 19, 2018
SMITHTOWN, N.Y., June 19, 2018 (Globe Newswire) iGambit, Inc. (OTCBB: IGMB) is pleased to announce that it has entered into a Letter of Intent (“LOI”) with Winpoint Health LLC.
The acquisition of Winpont Health LLC offers strategic synergies with our HealthDatix Inc. subsidiary, providing a new and unique opportunity for physicians to identify patients eligible for Annual Wellness Visits as well as Chronic Care Management, both of which are reimbursed by Medicare.
Winpoint Health is a New York-based chronic care management service company that monitors patients between office visits by leveraging both first-in-class technology and a fully trained clinical team of healthcare professionals.
HealthDatix identifies the patient’s eligibility for Medicare-reimbursed doctor visits to access and assist in the well-being and cultivation of a healthy lifestyle. Our WellDatix Annual Wellness Visit provides a comprehensive preventive care plan including all the preventive screening and services a patient requires to maintain a healthy, balanced life. By implementing HealthDatix’s superior Medicare-recommended care plan alongside Winpoint Health’s care managers to execute first in-class patient care delivery, we can ensure the patient is on track for reduced chronic condition episodes while lowering their cost of care.
The HealthDatix AWV/HRA also identifies those patients who require additional monitoring to improve their health. Our BioDatix Wristband wearable medical monitor offers round-the-clock monitoring, passively collecting data without affecting the patient’s routine. Utilizing the Winpoint care team and the BioDatix WristBand, patients are provided a clear path to improved health and lower out-of-pocket costs.
By implementing an effective technology-driven oversight and compliance program, our solution can drastically reduce the number of hospitalization rates, re-hospitalization rates, and augment nursing home placement. This approach will also greatly reduce overall medical spending.
John Salerno, Chairman of iGambit stated: We are very excited on this merger, it is a logical next step that creates substantial value for our customers and the stockholders of HealthDatix and Winpoint Health. It not only benefits patients and healthcare providers, but it expands the market reach for both entities creating a powerhouse of healthcare technology and a fluid patient delivery system.
Isaac Levy, of Winpoint stated:” “We are excited to combine our innovative white label chronic care management solution with the powerful healthdatix platform.”
The growth potential is well-documented. Eighty percent of Medicare beneficiaries have two or more chronic conditions, which is the qualifying criteria to enroll in Chronic Care Management (CCM) program. Over 71 cents of every healthcare dollar in the US is spent on those with multiple chronic conditions. The Centers for Medicare and Medicaid Services (CMS) is projecting that number of total beneficiaries to skyrocket close to 80 million by 2030.
The global wearable medical devices market size was valued at USD 3.9 billion in 2014 and is expected to grow with a CAGR of 28% over the forecast period. Increasing demand for technologically advanced wearable medical devices, rising awareness regarding physical fitness, advent of new smartphone-linked healthcare applications, and growing demand for wireless connectivity in the healthcare industry are the key factors propelling the overall industry. The BioDatix WristBand will be paired with our FDA-approved Electronic House Call as an additional leading-edge digital patient monitoring program for the Winpoint Health chronic care program. We anticipate it to be fully deployed by end of next quarter.
Pursuant to the LOI, IGI would buy all of the outstanding shares of “Winpoint” and would assume all of the business operations of “Winpoint”. “Winpoint” would operate as a wholly owned subsidiary of IGI.
Prior to or concomitant with closing Winpoint will have secured a $2,000,000 equity investment into Winpoint.
The consideration for the purchase would be as follows: Winpoint shareholders and the equity investors (collectively, “WP Shareholders”) shall receive IGI Common Shares equal to 65% of the issued and outstanding shares post Transaction.
iGambit Inc. estimates a closing within 60-90 days from the signing of the Letter of Intent and the commencement of due diligence.
The LOI has certain binding and non-binding obligations, and the transaction is subject to various conditions to closing, including satisfactory completion of due diligence, approval of the Company’s shareholders, if required, and definitive documentation.
A copy of the Form 8-K report may be accessed at www.sec.gov.
About HealthDatix
Healthy, Longer Lives, that’s our mission. Within the population of any group or organization there are people who are healthy and those that are at risk. Our mission is to aggregate their data and deliver accurate reporting necessary to make vital decisions on a course of treatment or education for those at risk. We empower you with the data needed to negotiate future health costs. We’re helping to shape the future of our nation’s health care system, with robust leveraging of technology that delivers value-based healthcare and payment without extra staff or additional efforts on the part of the caregiver. Our proprietary data analytics management uncovers new opportunities for health wellness visits and 24/7/365 monitoring of people with chronic conditions. For more information, please visit www.healthdatix.com.
About Winpoint Health, LLC
Winpoint Health, LLC combines technology, services, and our unique personal touch to deliver customized scalable plans to benefit both the provider and the patient. Our white labeled Chronic Care Management turnkey solution seamlessly enables a healthcare provider to increase its annual revenue and extend its patients’ office care into their homes with no upfront costs to either party, while empowering patients to take a more active role in managing their health. For more information, please visit www.winpointhealth.com
iGambit (OTCBB: IGMB) is a fully reporting publicly-held company. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release.
Safe Harbor:
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intends," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, including but not limited to, economic conditions, dependence on management, dilution to shareholders, lack of capital changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth, demand for products and services of the Company, newly developing technologies, its ability to compete, conflicts of interest related to party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition, and the ability of the Company to obtain additional financing. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
==============================================================
HealthDatix partners with Winpoint
May 8, 2018
SMITHTOWN, N.Y., May 8, 2018 (Globe Newswire) iGambit, Inc. (OTCBB: IGMB) is pleased to announce that the company’s wholly owned subsidiary, HealthDatix, has entered into a contract with Winpoint Health, LLC. Winpoint Health is a New York based chronic care management service company that monitors patients between office visits by leveraging, both first in-class technology and a fully trained clinical team of healthcare professionals.
It’s a known fact that 80% of Medicare beneficiaries have multiple chronic conditions and that over 71 cents of every healthcare dollar spend in the US is spent on those with multiple chronic conditions. By implementing an effective technology driven oversight and compliance program the companies can drastically reduce the number of hospitalization rates, rehospitalization rates and augment nursing home placement. This approach will also greatly reduce and overall medical spending.
HealthDatix’s WellDatix Annual Wellness Visit provides a comprehensive preventive care plan including all the preventive screening and services a patient requires to maintain a healthy, balanced life. By using both HealthDatix’s superior “Medicare recommended care plan” and Winpoint Health’s “care managers” to execute first in-class patient care delivery, we can ensure the patient is on track for reduced chronic condition episodes while lowering their cost of care.
The new frontier of healthcare requires team-based care where multiple healthcare providers offer a more focused and comprehensive patient-centered delivery model. This value-based model requires at risk healthcare providers to purchase outside services through partners with technology like the HealthDatix-Winpoint Health programs. This improves healthcare outcomes for the patient, and at the same time, reduces overall medical costs.
Additionally, the HealthDatix passive monitoring wearable will be paired with the FDA approved Electronic House as an additional, leading edge, digital patient monitoring program for the Winpoint Health chronic care program and we anticipate it to be fully deployed by end of next quarter.
About HealthDatix
Healthy, Longer Lives, that’s our mission. Within the population of any group or organization there are people who are healthy and those that are at risk. Our mission is to aggregate their data and deliver accurate reporting necessary to make vital decisions on a course of treatment or education for those at risk. We empower you with the data needed to negotiate future health costs. We’re helping to shape the future of our nation’s health care system, with robust leveraging of technology that delivers value-based healthcare and payment without extra staff or additional efforts on the part of the caregiver. Our proprietary data analytics management uncovers new opportunities for health wellness visits and 24/7/365 monitoring of people with chronic conditions. For more information, please visit www.healthdatix.com.
About Winpoint Health, LLC
Winpoint Health, LLC combines technology, services, and our unique personal touch to deliver customized scalable plans to benefit both the provider and the patient. Our white labeled Chronic Care Management turnkey solution seamlessly enables a healthcare provider to increase its annual revenue and extend its patients’ office care into their homes with no upfront costs to either party, while empowering patients to take a more active role in managing their health. For more information, please visit www.winpointhealth.com
iGambit (OTCBB: IGMB) is a fully reporting publicly-held company. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release.
Safe Harbor:
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intends," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, including but not limited to, economic conditions, dependence on management, dilution to shareholders, lack of capital changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth, demand for products and services of the Company, newly developing technologies, its ability to compete, conflicts of interest related to party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition, and the ability of the Company to obtain additional financing. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
==============================================================
HealthDatix partners with DocsInk
April 24, 2018
SMITHTOWN, N.Y., April 24, 2018 (GLOBE NEWSWIRE) iGambit, Inc. (OTCBB: IGMB) is pleased to announce that the company’s wholly owned subsidiary, HealthDatix, has entered into a mutually beneficial relationship with DocsInk. Networking with DocsInk will allow us to integrate and securely share information between our two systems to mutually benefit our shared clients, and streamline our operations.
HealthDatix, Inc. is pleased to announce their engagement with DocsInk, a cloud-based chronic care management (CCM) and team-based communication platform. HealthDatix’s WellDatix Annual Wellness Visit is the perfect precursor for identifying patients qualified for Chronic Care management. HealthDatix has partnered with DocsInk as our technology partner of choice to provide healthcare professionals with a seamless, easy to use integration of both services.
Todays revolutionary healthcare services require a team-based approach, where multiple healthcare providers join together to deliver personalized patient care plans. This value-based model requires purchasing outside services through business affiliations with technology providers in order to provide vastly improved healthcare outcomes for those individual patients.
HealthDatix's Annual Wellness Visit (AWV) solution provides a comprehensive patient care plan that is used by various healthcare providers. Our Annual Wellness Visit allows them to diagnose those patients that possess 2 or more chronic conditions that will last at least a year. The HealthDatix and DocsInk integration will automatically send that individual patients care plan to DocsInk, ensuring a seamless transition into a Chronic Care Management program for the ongoing treatment, and relief of that patient’s conditions.
We expect the integration of the two applications to be completed by the end of 2018 Q2.
In forming relationships with various healthcare providers, a network of extraordinary technology tools is established. That network delivers a sustainable and scalable model for improving healthcare quality, and lowering the overall cost of care.
About HealthDatix
Healthy, Longer Lives, that’s our mission. Within the population of any group or organization there are people who are healthy and those that are at risk. Our mission is to aggregate their data and deliver accurate reporting necessary to make vital decisions on a course of treatment or education for those at risk. We empower you with the data needed to negotiate future health costs. We’re helping to shape the future of our nation’s health care system, with robust leveraging of technology that delivers value-based healthcare and payment without extra staff or additional efforts on the part of the caregiver. Our proprietary data analytics management uncovers new opportunities for health wellness visits and the passive monitoring of people with chronic conditions. For more information, please visit www.healthdatix.com.
About DocsInk, LLC
DOCSINK is the only HIPAA secure messaging product to meet MACRA and MIPS standard, preparing organizations for the future of healthcare. DocsInk LLC owns and operates a charge capture and mobile healthcare communication platform for single doctors, multi-specialties, hospitals, and ACOs. Its DocsInk platform enables the users to submit bills, notify and activate the transition of care coordinators, and send notices of admission or discharge to the selected primary care or referring providers. The company’s DocsInk comprises a Web-based dashboard and a mobile application for charge capture, texting, discharge notification, telehealth, chronic care management and referral management applications. DocsInk LLC was incorporated in 2012 and is based in Wrightsville Beach, North Carolina. For more information, please visit www.docsink.com.
About iGambit Inc.
iGambit (OTCBB: IGMB) is a fully reporting publicly-held company. We are a company focused on pursuing specific medical strategies and objectives. These objectives have included, among others, the acquisition of medical technology companies with strong growth potential easily recognized in the public arena. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
==============================================================
iGambit Inc’s, HealthDatix signs Telehealth Wearables contract with Axcel Electronics
November 2, 2017
SMITHTOWN, N.Y., November 2, 2017 (Marketwire) iGambit, Inc. (OTCQB: IGMB) is pleased to announce that the company’s wholly owned subsidiary, HealthDatix, has entered into a contract with Axcel Electronics Thailand Co Ltd. (Axcel)
HealthDatix and Axcel signed a mutually exclusive supply agreement for the design and manufacture of Wearable Health Wrist Bands for use in conjunction with HealthDatix’s CareDatix solution and specifically its Electronic House Call FDA approved Tele-Health remote monitoring system.
The new exciting HealthDatix wearable called “BioDatix WristBand” units have been undergoing continuous testing in the USA for the past four months. The health bands fit your wrist, and can measure, report and graph trends in Heart Rate, Blood Pressure, Blood Oxygen and Electrocardiograms. Upon completion of testing, HealthDatix plans to submit its application for FDA approval to integrate it with the company's existing FDA approved back-end. HealthDatix believes this will put the company in a unique position with game changing technology, which will form a seamless end-to-end, sensor-to-server FDA approved and HIPAA compliant system which will revolutionize medical monitoring.
What is Tele-Medicine and Tele-Health;
https://www.americanwell.com/the-difference-between-telehealth-and-telemedicine
CareDatix Solution is a secure online web application that enables care managers to manage patients’ care plans in near real time. This application is the integral piece that connects patients using our Electronic House Call protocol with care managers.
Using the CareDatix FDA approved cloud application allows care providers and managers to remotely monitor patients between scheduled visits, increase care plan compliance, detect and intervene to minimize disease progression, and improve outcomes for patients with chronic illnesses and employees in the work place.
Global Telemedicine Industry
According to Medgadget, the global telemedicine market is estimated to grow from $25.53 billion in 2015 to $57.92 billion in 2020, with a compound annual growth rate (CAGR) of 17.85% over the next five years.
https://www.medgadget.com/2017/04/telemedicine-market-worth-57-92-billion-global-market-size-application-analysis-regional-outlook-2017-2020.html
Utilizing the BioDatix WristBand’s bluetooth capabilities, CareDatix collects the information on the patient. The wristbands will provide passive monitoring of the patient and provide exceptional reporting for the physician. The data collected from the health band will be collected via an iOT device, not via a tablet or smartphone. The patients’ vitals and baseline will be entered into the system at the time the device is assigned by the physician’s staff and any deviation from the baseline will generate alerts to the patient, caregiver and physician staff. This process is FDA approved, HIPAA compliant and easy to use.
Ongoing testing will continue over the next few months and we plan to be in a position to ship retail ready devices in the first quarter of 2018.
Jerry Robinson, HealthDatix CEO said “We are extremely excited to be working with the Axcel team. We have, throughout this wearables development, had the opportunity to offer feedback regarding our industry specific needs in creating this remarkable wearable. We are confident this wearable with our FDA approved, HIPAA compliant back end will transform and revolutionize the Telehealth and Telemedicine markets. We have begun to gain traction from the AWV business, and expect to have continued growth in the next two months of this quarter and stronger growth in quarter one of 2018. This coupled with the expected sales from the launch of our wearable technology, should prove to make early 2018 an exciting period for the company. Additionally, with strong sales from both sectors of our core business, we expect a significant 2018.
Axcel Electronics Thailand Co Ltd. www.axcel-electronics.com has been involved in electronic design and manufacturing for nearly 20 years in both OEM/ODM projects and own branded retail products through major retailers.
Karl St. George, the Axcel Electronics CEO, said that “this collaborative effort with HealthDatix focuses on bringing state of the art medical technology to the mobile patient to produce favorable outcomes and improve overall quality of life”.
About HealthDatix
Healthy, Longer Lives, that’s our mission. Within the population of any group or organization there are people who are healthy and those that are at risk. Our mission is to aggregate their data and deliver accurate reporting necessary to make vital decisions on a course of treatment or education for those at risk. We empower you with the data needed to negotiate future health costs. We’re helping to shape the future of our nation’s health care system, with robust leveraging of technology that delivers value-based healthcare and payment without extra staff or additional efforts on the part of the caregiver. Our proprietary data analytics management uncovers new opportunities for health wellness visits and 24/7/365 monitoring of people with chronic conditions. For more information, please visit www.healthdatix.com
About iGambit Inc.
iGambit (OTCBB: IGMB) is a fully reporting publicly-held company. We are a company focused on pursuing specific medical strategies and objectives. These objectives have included, among others, the acquisition of medical technology companies with strong growth potential easily recognized in the public arena. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
==============================================================
HealthDatix, signs contract with Endeavor Plus
October 9, 2017
SMITHTOWN, N.Y., October 9, 2017 (Marketwire) iGambit, Inc. (OTCBB: IGMB) is pleased to announce that the company’s wholly owned subsidiary, HealthDatix, has entered into a contract with Endeavor Plus.
HealthDatix will provide an online Health Risk Assessment (HRA) tool to facilitate the implementation of HealthDatix’s Individual Health Questions (IHQ). This tool will aid employers who participate in the Endeavor Plus Plan with the data analytics on their employee population.
Endeavor Plus, Inc., www.endeavorplus.com , is a consumer and technology-driven company that offers employers an opportunity to participate in a unique and innovative health plan program called the Endeavor Plus Plan. In addition, the company has created a sustainable ERISA & HIPAA compliant major medical health insurance solution for the small to mid-sized employers that, over time, is significantly less costly than the fully insured legacy carrier health insurance plans offered by the Affordable Care Act today.
Pat Dileo, the Endeavor Plus CEO, said that “this collaborative effort with HealthDatix focuses on offering employers and their employees a robust wellness program that helps them maintain better long-term health. Sustained better health leads to saving dollars, fewer trips to the medical providers and the fulfillment of an elevated quality of life.”
About HealthDatix:
The HealthDatix team is focused on the private commercial market, extending its platform to facilitate providing self- insured markets with a system to capture the data to augment their organizations wellness programs.
Wellness programs are using our Health Risk Assessment (HRA) to keep health care costs under control and to gain a better understanding of their employee’s health risks so that they can choose the health issues on which to focus their wellness programs.
Our WellDatix application delivers an HRA application that provides the employer with the data analytics on their entire population and a Personalized Preventive Plan (PPP) for their employee’s, thus providing an incentive for the employee to complete the HRA and the employer to effectively control healthcare costs.
HealthDatix is focused on developing a strong distribution platform by working with both Vendor Partners and Channel Partners to facilitate the implementation of both the Annual Wellness Visit (AWV) program, and the Health Risk Assessment (HRA) program.
HealthDatix has formed two distinct vertical platforms to best serve its clientele:
Government:
-Traditional Medicare,
-Managed Service Organization (MSO)
-Accountable Care Organization (ACO)
- Medicare Advantage Plan (MAP)
-Medicaid
Private:
Commercial Payors
BlueCross, BlueShield, United Healthcare, Cigna, Aetna (BUCA’s)
Self Insured
Private Pay
Third Party Administrators (TPA)
==============================================================
HealthDatix Channel Partners Sign Two Contracts Utilizing the HealthDatix Platform
August 23, 2017
SMITHTOWN, NY--(Marketwired – (August 23, 2017) (OTCQB: IGMB) iGambit Inc. is pleased to announce that one of its Channel Partners has signed two contracts, utilizing the HealthDatix platform, with two large mid-western health systems. The contracts are with the Primary Care Physicians practices that are affiliates of the hospital systems. The practices have approximately 25,000 patients.
Our focus is on developing a strong distribution platform by working with vendor partners and Channel Partners to facilitate the implementation of the HealthDatix platform to provide medical organizations with easy to use full service solution to perform Annual Wellness Visits (AWV), Health Risk Assessment (HRA) and initiate Personal Prevention Plans (PPP). Health Risk Assessments have been implemented by Medicare to insure that patients receive care that increases their overall health while at the same time decreases their incidents of readmission due to chronic illness.
Salerno, Chairman of iGambit stated, “I am extremely pleased that our HealthDatix team has successfully initiated the process of rollout for our healthcare program. These contracts represent just the beginning of our national rollout and I expect that our team will continue our HealthDatix rollout at a swift pace throughout this quarter.”
About iGambit Inc: iGambit (OTCQB: IGMB) is a fully reporting publicly-held company. We are a company focused on pursuing specific medical strategies and objectives. These objectives have included, among others, the acquisition of medical technology companies with strong growth potential easily recognized in the public arena. We believe that the back-ground of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner. We expect to work to assume an active role in the development and growth of the new company, providing both strategic guidance and operational support. The management of iGambit believes that it can leverage its collective expertise to help position the combined company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
==============================================================
HealthDatix initiates pilot program with West Florida Health Network
August 17, 2017
SMITHTIOWN, NY-(Marketwire-August 17, 2017) - iGambit Inc. (OTCBB: IGMB) is pleased to announce that the company’s wholly owned subsidiary, HealthDatix, Inc. has entered into a pilot program with West Florida Health Network (WFHN), which is a Community Integrated Network (CIN).
The West Florida Health Network has been selected by two large Tampa Bay healthcare systems to be their provider of choice for their employee health benefit plans.
HealthDatix will provide the online Health Risk Assessment (HRA) tool to facilitate the implementation of the HRA and provide WFHN the data analytics on their employee population. Additionally, HealthDatix will provide a Personal Preventive Plan (PPP) to the employee and their dependents to assist in maintaining a healthy life style.
The two health systems have approximately 22,000 covered lives.
The response from the Health Care Providers has been very positive. In order to best deal with the number of inquiries, HealthDatix has deemed it necessary to form two distinct vertical platforms to best serve its clientele:
Government:
-Traditional Medicare,
-Managed Service Organization (MSO)
-Accountable Care Organization (ACO)
- Medicare Advantage Plan (MAP)
-Medicaid
Private:
- Commercial Payors
- BlueCross, BlueShield, United Healthcare, Cigna, Aetna (BUCA’s)
- Self Insured
- Private Pay
- Third Party Administrators (TPA)
Our focus is on developing a strong distribution platform by working with both Vendor Partners and Channel Partners to facilitate the implementation of both the Annual Wellness Visit (AWV) program, and the Health Risk Assessment (HRA) program.
The HealthDatix sales team has focused on the private commercial market, extending its platform to facilitate providing self- insured markets with a system to capture the data to augment their organizations wellness programs.
Wellness programs are using the Health Risk Assessment (HRA) to keep health care costs under control and to gain a better understanding of their employee’s health risks so that they can choose the health issues on which to focus their wellness programs.
The WellDatix application is the only HRA application that provides the employer with the data analytics on their entire population and a Personalized Preventive Plan (PPP) for their employee’s, thus providing an incentive for the employee to complete the HRA and the employer to effectively control healthcare costs.
About iGambit Inc: iGambit (OTCBB: IGMB) is a fully reporting publicly-held company. We are a company focused on pursuing specific medical strategies and objectives. These objectives have included, among others, the acquisition of medical technology companies with strong growth potential easily recognized in the public arena. We believe that the back-ground of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner. We expect to work to assume an active role in the development and growth of the new company, providing both strategic guidance and operational support. The management of iGambit believes that it can leverage its collective expertise to help position the combined company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
==============================================================
Letter to Shareholders
July 26, 2017
To our Shareholders,
Recent Company Events
During the past several months some significant events have occurred at iGambit. On February 14, 2017 we acquired HubCentrix, Inc. (HubCentrix) and on April 6, 2017 we acquired the assets of the CyberCare Health Network Division from EncounterCare Solutions Inc. (ECSL). Both are in the health wellness business. Their services are complementary and are operating under our wholly owned subsidiary HealthDatix, Inc. (HealthDatix).
In addition, on June 30, 2017 we sold off our wholly owned subsidiary Wala Inc., doing business as ArcMail Technologies (ArcMail), resulting in an elimination of approximately $6 million in liabilities from our balance sheet.
Welcome New Shareholders
As a result of the ECSL transaction we have gained the ECSL shareholders as new valued shareholders of iGambit. We welcome you as you join our existing loyal iGambit shareholders and look forward to a prosperous future together.
Our New Focus
Previously we were a company focused on the technology markets. With the two recent acquisitions and the ArcMail sale, we now tailor our focus entirely on the medical technology markets. Our mission is the expansion of HealthDatix.
HealthDatix provides a new and unique opportunity for physicians to identify patients eligible for both “Annual Wellness Visits” (AVW) as well as “Chronic Care Management” both of which are reimbursed by Medicare. HealthDatix’s identifies the patient’s eligibility for Medicare reimbursed doctor visits to access and assist in the well-being and cultivation of a healthy lifestyle. Additionally HealthDatix provides an FDA approved, Medicare covered platform, for continuous management of chronic care patients. Our continuous care platform can be tailored for individual care and health management of patients susceptible to chronic illness.
The HealthDatix platform is also designed to accumulate information from any TeleMedicine or wearable device. This includes our own wearable medical watch, under development, that will continuously collect and trend data.
Our AWV platform technology is complete and our Chronic Care Monitoring Platform and Electronic House Call technology is complete and FDA approved. We have launched the AWV program and have started to recognize revenue. We expect the revenue to grow steadily during 2017 with significant growth anticipated during 2018.
Our medical wearable watch is currently under development and we anticipate its completion some time in 2018.
The Market Potential
There are approximately 57 million Medicare participants currently according to the Centers for Medicare and Medicaid Services, with the number forecast to rise to approximately 79 million in 2030. 70% of Medicare patients (or 40 million) require an annual wellness visit exam (AWV). HealthDatix offers software that facilitates the AWV.
By the end of 2018 all Advantage Care members (currently approximately 19 million) will be required to have an AWV to continue to qualify for Medicare. Also, the onetime sale of a Medical-Wearable offers additional potential revenue, which includes a monthly recurring monitoring fees, particularly for those patient’s identified as eligible for Chronic Care Monitoring.
The approximately 10 million patients of Medical Service Organizations (MSO) and approximately 156 million members of Private Health Plans represent opportunities for our Company using our digital health monitoring systems.
Conclusion
In conclusion, I am proud of the accomplishments we have made to date and am extremely enthused about our prospects going forward. On behalf of all of us at iGambit, I thank all of our stakeholders for your continued support and look forward to announcing additional milestones.
Sincerely,
John Salerno
Chairman& CEO
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commissio
==============================================================
iGambit Announces Sale of ArcMail Technologies and $6,000,000 liabilities reduction from Balance Sheet
July 5, 2017
SMITHTOWN, NY, July 5, 2017 Marketwire/ -- iGambit Inc. (OTCQB: IGMB), announced that on June 30, 2017 it completed the sale of its wholly owned subsidiary WaLa, Inc. doing business as ArcMail Technologies (“ArcMail”) to Rory T. Welch. CEO and President of ArcMail (“Welch”), in accordance with a Stock Purchase Agreement (the “Purchase Agreement”) by and between the Company and Welch.
Pursuant to the Purchase Agreement, the total consideration to be paid for the outstanding capital stock of ArcMail is remittance of 10,000,000 shares of iGambit Common stock previously issued to Welch.
Furthermore, as per the Purchase Agreement, iGambit’s operations of the business ended March 31, 2017 and Welch’s operation of the business is effective as of April 1, 2017.
From an investor perspective, the effect of the transaction results in reducing iGambit’s overall outstanding balance sheet liabilities by approximately 91% with over $6,000,0000 in debt and other liabilities being removed from the balance sheet.
A copy of the Form 8-K report may be accessed at www.sec.gov.
As disclosed in our 2016 Form10-K, effective October 1, 2016, management decided to dispose of its subsidiary Arcmail and entered into a letter of intent on March 1, 2017 to sell Arcmail in a stock exchange to the CEO of Arcmail. As a result of the decision, IGMB reported the financial results of the ArcMail business as discontinued operations in its 2016 annual report filed on Form 10-K and March 31, 2017 quarterly report filed on Form 10-Q with the Securities and Exchange Commission. In addition, in connection with management’s decision to sell Arcmail, an impairment charge to discontinued operations of $6,263,320, and amortization of $441,837 was charged to discontinued operations during the year ended December 31, 2016.
"Although ArcMail has been a valuable part of iGambit, this transaction allows us to focus on our new tailored strategy of pursuing specific medical technology strategies and objectives through our recently acquired business HealthDatix, Inc." said John Salerno, iGambit CEO and Chairman. “We wish Mr. Welch continued success with ArcMail.”
The goal of HealthDatix is to identify the patient’s eligibility for Medicare reimbursed doctor visits to access and assist in the well-being and cultivation of a healthy lifestyle. Additionally HealthDatix is able to provide an FDA approved, Medicare covered platform, for continuous management of chronic care patients. Our continuous care platform will be tailored for individual care and health management of patients susceptible to chronic illness. This will include our wearable medical watch to be released in the near future.
About iGambit Inc: iGambit (OTCBB: IGMB) is a fully reporting publicly-held company. We are a company focused on pursuing specific medical strategies and objectives. These objectives have included, among others, the acquisition of medical technology companies with strong growth potential easily recognized in the public arena. We believe that the back-ground of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner. We expect to work to assume an active role in the development and growth of the new company, providing both strategic guidance and operational support. The management of iGambit believes that it can leverage its collective expertise to help position the combined company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
==============================================================
iGambit Announces Dr. Robert Randelman joins its Advisory Board
June 14, 2017
SMITHTOWN, NY, June 14, 2017 Marketwire -- iGambit Inc. (OTCQB: IGMB), announced that Robert Randelman has joined its Senior Advisory Board.
Dr. Robert (Rob) Randelman, Ph.D joins Dr. Benedict S Maniscalco as a member of its’ Senior Advisory Board effective June 15, 2017. This follows the acquisition of HubCentrix and the CyberCare Health Network Chronic Care Management System. Both companies operate as HealthDatix, Inc.
The goal of HealthDatix is to identify the patient’s eligibility for Medicare reimbursed doctor visits to access and assist in the well-being and cultivation of a healthy lifestyle. Additionally HealthDatix will be able to provide an FDA approved, Medicare covered platform, for continuous management of chronic care patients. Our continuous care platform will be tailored for individual care and health management of patients susceptible to chronic illness. This will include CyberCare’s wearable medical watch.
The addition of Dr. Randelman to iGambit’s Advisory Board brings on a senior executive with strong technical, management and international experience with a record of growth in technically-based businesses. As a company Chairman and CEO/President he drove strategy in M&A, IP Licensing, market expansion and technology development. Efforts that resulted in dynamic growth with P&L responsibility for a company with over $140 million annual revenue, and over 500 employees in 7 countries. He has been successful in developing international markets in Latin America, Europe and China.
Currently, Dr. Randelman is Chief Executive Officer of Trident Science, LLC, a privately held scientific products and consulting company. Prior to his current role, he was the a Divisional Chief Executive and Executive Board Member for Halma, PLC. His career has spanned global executive roles in sales, marketing, operations and technology with Ocean Optics, Inc, VeriFone, Inc., Hewlett-Packard Corp and Exxon-Mobil Corp.
Dr. Randelman earned a BS degree in Chemistry/Physics from Ursinus College, as well as Masters and Ph.D degrees in Chemical Engineering from Lehigh University.
Regarding publications and Patents, Robert’s credits include: over 20 papers and publications in diverse areas of science, technology and technology management; also, one patent and 12 registered processes, spanning a wide range of technologies.
John Salerno, Chairman of iGambit, “We are very pleased and honored to have someone of Robert Randelman’s caliber join our Senior Advisory Board. His management and work experience together with others that will be joining us will set a standard by which we deliver excellence in services and technology as we move forward.”
About iGambit Inc.: iGambit (OTCBB: IGMB) is a fully reporting publicly-held company. We are a company focused on pursuing specific medical strategies and objectives. These objectives have included, among others, the acquisition of medical technology companies with strong growth potential easily recognized in the public arena. We believe that the back-ground of our management, our Board of Directors and our Advisory Board in the medical and technology markets is a valuable resource that makes us a desirable business partner. We expect to work to assume an active role in the development and growth of the new company, providing both strategic guidance and operational support. The management of iGambit believes that it can leverage its collective expertise to help position the combined company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are ‘forward-looking statements’ within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
==============================================================
iGambit Announces Dr. Benedict S. Maniscalco joins its Advisory Board
May 8, 2017
SMITHTOWN, NY, May 8, 2017 Marketwire -- iGambit Inc. (OTCQB: IGMB), announced that Dr. Benedict S. Maniscalco has joined its Senior Advisory Board.
This follows the acquisition of HubCentrix and the CyberCare Health Network Chronic Care Management System. Both companies operate as HealthDatix, Inc.
The goal of HealthDatix is to identify the patient’s eligibility for Medicare reimbursed doctor visits to access and assist in the well-being and cultivation of a healthy lifestyle. Additionally HealthDatix will be able to provide an FDA approved, Medicare covered platform, for continuous management of chronic care patients. Our continuous care platform will be tailored for individual care and health management of patients susceptible to chronic illness. This will include CyberCare’s wearable medical watch.
Dr. Benedict S. Maniscalco, M.D. received his medical degree from the Duke University School of Medicine in 1967. He interned at Grady Memorial Hospital in Atlanta and did his junior and senior residencies at Emory University Affiliated Hospitals, followed by a fellowship in Cardiovascular diseases from 1973-1975. He is licensed to practice in both Florida and Georgia and is certified by the American Board of Internal Medicine and the American Sub-Specialty Board in Cardiovascular disease.
From 1976 through early 1979 Dr. Maniscalco was on the faculty of the University of South Florida School of Medicine, division of Cardiology in Tampa, Florida. Later in 1979, Dr. Maniscalco was recruited to establish the cardiac catheterization laboratory at St. Joseph’s hospital in Tampa. He subsequently expanded the program and founded the nationally recognized St. Joseph’s Heart Institute which served as a model for cardiovascular programs throughout the country.
Dr. Maniscalco served as Chief of Cardiology and Director of the cardiac catheterization laboratory until from its founding through 2001. In this capacity, many of the innovative procedures and technology of modern cardiovascular services were implemented. While Director of the Heart Institute, Dr. Maniscalco was an officer and director of a large multi-specialty cardiovascular group practice.
Over his distinguished career, Dr. Maniscalco has served as a consultant, opinion leader and speaker for numerous companies in both the pharmaceutical and device industry. He has lectured throughout the country for both medical and industry colleagues. He has been involved and led many research efforts in both clinical and non-clinical areas of investigation.
Dr. Maniscalco has been a member of and served many professional medical societies. In the American College of Cardiology, he served in many capacities at the local, state and national levels. He has made significant contributions on numerous committees and in many capacities including his tenure as President and Governor of the Florida Chapter of the American College of Cardiology. His specific contributions in the areas of health policy and socioeconomic issues were numerous.
Today, Dr. Maniscalco continues his devotion to patients in a consultative and prevention cardiology practice in Tampa, Florida and on an international basis as CEO and Chairman of Heartbeat International Foundation (HBI)! HBI provides pacemakers, defibrillators and other cardiac services to the less fortunate in developing countries of the world. Over 15,000 patients lives have been saved or changed by the efforts of Heartbeat International and the many volunteer physicians and colleagues worldwide.
John Salerno, Chairman of iGambit, “We are very pleased to have Dr. Maniscalco join us in our new business opportunity. His experience and knowledge together with others that will be joining us will set a standard by which we deliver excellence in services and technology.”
About iGambit Inc: iGambit (OTCBB: IGMB) is a fully reporting publicly-held company. We are a company focused on pursuing specific medical strategies and objectives. These objectives have included, among others, the acquisition of medical technology companies with strong growth potential easily recognized in the public arena. We believe that the back-ground of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner. We expect to work to assume an active role in the development and growth of the new company, providing both strategic guidance and operational support. The management of iGambit believes that it can leverage its collective expertise to help position the combined company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are ‘forward-looking statements’ within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
==============================================================
April 07, 2017
IGAMBIT Announces Acquisition of CyberCare Health Network
SMITHTOWN, NY--(Marketwired - Apr 6, 2017) - iGambit Inc. (OTCQB: IGMB), announced that on April 6, 2017 it acquired the CyberCare Health Network Division from EncounterCare Solutions Inc. (ECSL). Under the terms of the agreement iGambit, bought certain assets of EncounterCare. Payment was made in the form of IGMB stock.
CyberCare will operate as a division of the recently acquired HubCentrix Company, whose new name is HealthDatix, Inc.
A copy of the Form 8-K report may be accessed at www.sec.gov.
The acquisition of HubCentrix and the CyberCare Health Network Chronic Care Management System provides a new and unique opportunity for physicians to identify patients eligible for both "Annual Wellness Visits" as well as "Chronic Care Management" both of which are reimbursed by Medicare.
iGambit also hopes to close on the acquisition of CyberCare Health Division from EncounterCare Solutions, Inc. ("ECSL") within the next thirty (30) days. The Letter of Intent entered into with ECSL was previously announced on August 15, 2016. A copy of the Form 8-K report may be accessed at www.sec.gov
The acquisition of HubCentrix and the CyberCare Health Network Chronic Care Management System provides a new and unique opportunity for physicians to identify patients eligible for both "Annual Wellness Visits" as well as "Chronic Care Management" both of which are reimbursed by Medicare.
The goal of HealthDatix will be to identify the patient's eligibility for Medicare reimbursed doctor visits to access and assist in the well-being and cultivation of a healthy lifestyle. Additionally HealthDatix is able to provide an FDA approved, Medicare covered platform, for continuous management of chronic care patients. Our continuous care platform will be tailored for individual care and health management of patients susceptible to chronic illness.
The HealthDatix platform is designed to accumulate information from any TeleMedicine or wearable device.
This includes CyberCare's own wearable medical watch, a wearable device under development, that will continuously collect and trend data.
Key Health Parameters:
Heart Rate
Blood Pressure
Rest/Wake/Activity
SPO2 (Oxygenation of blood)
Key Cardiac Function ("Mini-ECG")
Different than other devices on the market:
Patented Instrumentation
Medically accurate
Designed to provide data directly to a health care provider through HealthDatix solution,
Share real-time information with health care providers and family
Provides better, and earlier, identification of patient health issues and treatment compliance
The completed wearable, when paired with the CyberCare Health Network Chronic Care Management System, will become part of the FDA approved chronic care management system.
John Salerno, Chairman of iGambit,: "As I previously stated we are very pleased to have this new business opportunity which we believe will increase our stockholders value. Our management team and advisors are very accomplished at introducing and administering rapid growth technology services. We anticipate that our exciting newly combined entity HealthDatix, will have the professionals in place to competently deal with the accelerated growth curve necessary to meet the needs of physician community throughout the country.
Ronald Mills Sr., CEO of EncounterCare stated; I am very pleased that we have been able to successfully complete this deal with HealthDatix and iGambit. The HealthDatix management team led by Jerry Robinson, President, has put together a very exciting program that I believe will benefit the medical community and which, I also believe will bring significant value to EncounterCare and our stockholders.
About iGambit Inc: iGambit (OTCQB: IGMB) is a fully reporting publicly-held company. We are a company focused on pursuing specific medical strategies and objectives. These objectives have included, among others, the acquisition of medical technology companies with strong growth potential easily recognized in the public arena. We believe that the back-ground of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner. We expect to work to assume an active role in the development and growth of the new company, providing both strategic guidance and operational support. The management of iGambit believes that it can leverage its collective expertise to help position the combined company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
Investor Relations Contacts:
Bill Robertson
Ph. No. 604 837 3835
==============================================================
Feb 15, 2017
iGambit Announces Acquisition of HUBCENTRIX INC. A Leading Provider of Healthcare Technology
SMITHTOWN, NY--(Marketwired - Feb 15, 2017) - iGambit Inc. (OTCQB: IGMB) announced that on February 14, 2017 it acquired HubCentrix, Inc. (HubCentrix) via a Stock Exchange Agreement.
A copy of the Form 8-K report may be accessed at www.sec.gov.
HubCentrix will initially operate as a wholly-owned subsidiary of iGambit and the name will be changed to HealthDatix Inc. ("HealthDatix").
iGambit also hopes to close on the acquisition of CyberCare Health Division from EncounterCare Solutions, Inc. ("ECSL") within the next thirty (30) days. The Letter of Intent entered into with ECSL was previously announced on August 15, 2016. A copy of the Form 8-K report may be accessed at www.sec.gov
The acquisition of HubCentrix and the CyberCare Health Network Chronic Care Management System provides a new and unique opportunity for physicians to identify patients eligible for both "Annual Wellness Visits" as well as "Chronic Care Management" both of which are reimbursed by Medicare.
The goal of HealthDatix will be to identify the patient's eligibility for Medicare reimbursed doctor visits to access and assist in the well-being and cultivation of a healthy lifestyle. Additionally HealthDatix will be able to provide an FDA approved, Medicare covered platform, for continuous management of chronic care patients. Our continuous care platform will be tailored for individual care and health management of patients susceptible to chronic illness. This will include CyberCare's wearable medical watch.
John Salerno, Chairman of iGambit, stated: "We are very pleased to have this new business opportunity which we believe will increase our stockholders value. Our management team and advisors are very accomplished at introducing and administering rapid growth technology services. We anticipate that our exciting newly combined entity HealthDatix, will have the professionals in place to competently deal with the accelerated growth curve necessary to meet the needs of physician community throughout the country.
Jerry Robinson, President of HubCentrix, stated that he is excited to team up with the management group at iGambit. The combined management team will consolidate to provide an extremely focused group effort to plan and execute corporate strategies for HealthDatix moving forward. My personal background is in marketing management as well as product launch, two areas that I am truly excited to bring to our new products rollout. One of the HealthDatix goals will be to initiate a progressive and effective marketing campaign to introduce our newly combined services to the healthcare marketplace and insurance industry.
About HubCentrix: is located in St. Petersburg, Florida and serves clients throughout the U.S. The company has been at the forefront of web-based collaboration and digital asset management. HubCentrix has a special expertise in streamlining the process of capturing and managing information in the document-intensive medical field.
About iGambit Inc.: iGambit (OTCBB: IGMB) is a fully reporting publicly-held company. iGambit (OTCQB: IGMB) is a fully reporting publicly-held company. We are a diversified company pursuing specific technology strategies and objectives. These objectives have included, among others, the acquisition of early-stage technology companies with strong growth potential easily recognized in the public arena. We believe that the back-ground of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner. We expect to work to assume an active role in the development and growth of the new company, providing both strategic guidance and operational support. The management of iGambit believes that it can leverage its collective expertise to help position the combined company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our web-site does not comprise a part of this press release.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward-looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
Investor Relations Contacts:
Bill Robertson
Ph. No. 604 837 3835
==============================================================
August 26, 2016
HubCentrix Inc. and iGambit Inc. Sign Letter of Intent for iGambit Inc. to Acquire the Assets of HubCentrix Inc.
SMITHTOWN, NY--(Marketwired - Aug 26, 2016) - HubCentrix and iGambit Inc. (OTCQB: IGMB) sign LOI.
Under the terms of the LOI, iGambit Inc. will acquire substantially all the assets of HubCentrix Inc. and will assume certain specifically identified liabilities. Payment for the acquisition will be made in the form of iGambit common stock.
iGambit Inc. and HubCentrix Inc. will collaborate in the preparation of a Asset Purchase Agreement.
iGambit Inc. estimates a closing within 45-60 days from the signing of the Letter of Intent and the commencement of due diligence. iGambit Inc. will use its best efforts to speed the transaction to a closing. The LOI has certain binding and non-binding obligations, and the transaction is subject to various conditions to closing, including satisfactory completion of due diligence, approval of the Company’s shareholders, if required, and definitive documentation. A copy of the Form 8-K report may be accessed at www.sec.gov John Salerno, Chairman of iGambit, stated, “We feel their qualified technical team and marketing and brand identity skills are the perfect complement to our pending CyberCare Health Network acquisition. Moreover HubCentrix’s newly launched wellness management software further enhances the ability for CyberCare to fulfill its mission and grow rapidly as the new industry gains momentum.” Jerry Robinson, CEO of HubCentrix, stated, “We see significant synergy between our companies’ offerings. The HubCentrix Annual Wellness Visit Portal automates the process by allowing the patient or provider to complete a Health Risk Assessment (HRA) online. Our algorithm produces detailed patient reports, physician reports, and summary reports for billing. The HRA identifies those patients who are at risk for chronic conditions, allowing the physician and the patient to be pro-active on addressing issues before they become life-threatening and costly. As these chronic care patients are identified the need for CyberCare’s Electronic Housecall system and wearable medical devices expands.” For more information, please visit www.cybercarehn.com. The importance of an Annual Wellness Visit (AWV) is so valued by Medicare that this preventive care is provided at no cost. The AWV is a Medicare-sanctioned, wellness program provided free of cost to medicare patients 66+. There are over 44 million medicare recipients and less than 12% are enrolled in the AWV. The HubCentrix AWV application was designed specifically for medi-care patients; however, the HRA is a standardized method of collecting health risk data that is used by multiple organizations to identify the health risks of their population.
About: HubCentrix Inc.
HubCentrix is located in St. Petersburg, Florida and serves clients throughout the U.S. The company has been at the forefront of web-based collaboration and digital asset management. HubCentrix has a special expertise in streamlining the process of capturing and managing information in the document-intensive medical field.
For more information, please visit www.hubcentrix.com.
About: iGambit Inc:
iGambit (OTCQB: IGMB) is a fully reporting publicly-held company. We are a diversified company pursuing specific technology strategies and objectives. These objectives have included, among others, the acquisition of early-stage technology companies with strong growth potential easily recognized in the public arena. We believe that the background of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner. We expect to work to assume an active role in the development and growth of the new company, providing both strategic guidance and operational support. The management of iGambit believes that it can leverage its collective expertise to help position the combined company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our website does not comprise a part of this press release.
Safe Harbor:
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intends," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, including but not limited to, economic conditions, dependence on management, dilution to shareholders, lack of capital changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth, demand for products and services of the Company, newly developing technologies, its ability to compete, conflicts of interest related to party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition, and the ability of the Company to obtain additional financing. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
Contact:
Bill Robertson
Ph. No. 604 837 3835
==============================================================
Nov 10, 2015
IGAMBIT Announces Acquisition of ArcMail. A Leading Provider of Email Management Solutions.
iGambit Announces Acquisition of ArcMail, a Leading Provider of Email Management Solutions
SMITHTOWN, NY--(Marketwired - Nov 10, 2015) - iGambit Inc. (OTCQB: IGMB), a diversified holding company, announced that on November 4, 2015 it acquired Wala, Inc doing business as ArcMail Technology (ArcMail) via a stock purchase agreement. ArcMail will operate as a wholly owned subsidiary of iGambit.
A copy of the Form 8-K report may be accessed at www.sec.gov.
Rory Welch, CEO of ArcMail, states, "ArcMail is very excited about becoming an iGambit company. Their exceptional leadership, core values of integrity and service to others and strong record of collaboration are a perfect fit for our corporate mission and vision. This partnership will allow us to continue to grow and advance our technology services."
John Salerno, Chairman and CEO of iGambit, said, "We have known and worked with ArcMail for several years to consummate this acquisition. We believe that both companies will benefit from ownership in the iGambit holding company model -- a model that offers significant growth potential. I am pleased to report that we have found a terrific opportunity for iGambit, ArcMail and our stakeholders in this combination. We look forward to having a close and rewarding relationship with Rory Welch and the ArcMail team as they seek to continue on their mission."
About iGambit Inc: iGambit (OTCQB: IGMB) is a fully reporting publicly-held company. We are a diversified holding company pursuing and evaluating a number of strategic objectives. These objectives include, among others, the potential acquisition of early-stage technology companies with strong growth potential easily recognized in the public arena. We believe that the background of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner to the companies that we are seeking to acquire. When we acquire a company, we work to assume an active role in the development and growth of the company, providing both strategic guidance and operational support. Once a company joins our partner company network, our collective expertise is leveraged to help position that company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our website does not comprise a part of this press release.
About ArcMail: ( www.arcmail.com ), ArcMail is a leading provider of simple, secure and cost-effective email and enterprise archiving and management solutions. Honored with the Network Products Guide Product Innovation Award, ArcMail was founded to help companies and public sector organizations implement effective email archiving programs, boost email server performance and satisfy regulatory requirements. With the rapid growth of email usage, the Shreveport, LA-based company addresses a need for simple, secure email archiving that is affordable for small businesses yet robust enough to handle the demands of enterprise companies and government entities. ArcMail's solution, the Defender, was developed to provide cost-effective email archiving hardware that improves the user experience, reduces the load on IT resources and safely secures the business information contained in emails, all in an easy-to-use appliance. We believe the Defender is the best email archiving solution for organizations with anywhere from 5 to 5,000+ mailboxes across a broad section of industries. Companies and organizations such as: Behr Paints, State of New York Metropolitan Transportation Authority, St. Louis Public Schools and the Canadian Parliament have all turned to ArcMail for efficient email storage. ArcMail has also been listed by leading business analyst companies who report on email archiving appliance vendors.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
CONTACT:
Investor Relations Contact:
iGambit Inc.
John Salerno
CEO
631-670-6777
john@igambit.com
Howard Gostfrand
President
American Capital Ventures
305-918-7000
hg@amcapventures.com
www.amcapventures.com
==============================================================
Nov 11, 2015
IGAMBIT Announces Sale of Gotham Subsidiary
Press Release: iGambit Inc. – Tuesday November 11, 2015 2 PM EST
SMITHTOWN, NY., November 11, 2015 Marketwire/ -- iGambit Inc. (OTCQB: IGMB), a diversified holding company, announced that on November 5, 2015, through its wholly owned subsidiary Gotham Innovation Lab, Inc. (“Gotham”) it sold certain assets of the Gotham business to VHT, Inc (“VHT”).
A copy of the Form 8-K report may be accessed at www.sec.gov.
John Salerno, Chairman and CEO of iGambit, said, “Gotham has been a useful and rewarding subsidiary and we wish VHT much success with this new acquisition. We will use the proceeds of the sale to further our business efforts with our recently acquired email archiving management solutions business, ArcMail.”
About iGambit Inc: iGambit (OTCBB: IGMB) is a fully reporting publicly-held company. We are a diversified holding company pursuing and evaluating a number of strategic objectives. These objectives include, among others, the potential acquisition of small to medium size businesses. We believe that the background of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner to the companies that we are seeking to acquire. When we acquire a company, we work to assume an active role in the development and growth of the company, providing both strategic guidance and operational support. Once a company joins our partner company network, our collective expertise is leveraged to help position that company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our website does not comprise a part of this press release.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
CONTACT: Investor Relations Contact:
iGambit Inc.
John Salerno, CEO
631-670-6777
john@igambit.com
Howard Gostfrand
President
American Capital Ventures
305-918-7000
hg@amcapventures.com
www.amcapventures.com
==============================================================
May 19, 2015
iGambit Inc. Retains American Capital Ventures for Investor Relations Services
SMITHTOWN, NY--(Marketwired - May 19, 2015) - iGambit Inc. (OTCQB: IGMB), a diversified holding company, today is pleased to announce that it has engaged American Capital Ventures ("ACV"), a boutique provider of comprehensive investor relations, financial marketing and capital advisory services to the micro- and small-cap community.
iGambit Inc.'s Chief Executive Officer and Chairman of the Board, John Salerno commented, "iGambit Inc. has been in aggressive pursuit of a successful, financially sound and growing acquisition since 2013 and are thrilled to have found it in United Fertility Centers of America (UFCA). Given this imminent and important development in our business, we found it pertinent to begin communicating our business, their business and our combined long-term value proposition to both the public and the investment community ASAP. ACV, an experienced firm specializing in micro-cap companies, has been brought on to assist us in that as well as improving our visibility in the market, and expanding our shareholder base. We look forward to working with their team to enhance our communication and bring greater value to our shareholders moving forward."
Mr. Gostfrand stated, "iGambit brings to the table a solid track record of execution, collaboration and experience in building multi-million dollar businesses. Their recent LOI of UFCA, and entry into the growing assisted reproductive technology and services field, presents a very compelling value proposition for shareholders and the investment community, alike. We're pleased to work with their exceptional management team to communicate this opportunity to shareholders and the street."
About iGambit Inc.: iGambit (OTCQB: IGMB) is a fully reporting publicly-held company. We are a diversified holding company pursuing and evaluating a number of strategic objectives. These objectives include, among others, the potential acquisition of small to medium size businesses. We believe that the background of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner to the companies that we are seeking to acquire. When we acquire a company, we work to assume an active role in the development and growth of the company, providing both strategic guidance and operational support. Once a company joins our partner company network, our collective expertise is leveraged to help position that company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our website does not comprise a part of this press release.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
CONTACT:
Investor Relations Contact:
iGambit Inc.
John Salerno
CEO
631-670-6777
john@igambit.com
==============================================================
May 15, 2015
iGambit Files Form 8-K, Announces Execution of Letter of Intent to Acquire United Fertility Centers of America May 13, 2015
SMITHTOWN, N.Y., May 13, 2015 (GLOBE NEWSWIRE) -- iGambit Inc. (OTCQB:IGMB), a diversified holding company, announced that on May 12, 2015 it entered into a Letter of Intent ("LOI") with United Fertility Centers of America (UFCA), which manages specialty outpatient fertility clinics. Pursuant to the LOI, at closing, iGambit will buy all the assets of UFCA and will assume certain specifically identified operating liabilities of UFCA. The assets and liabilities of UFCA will be placed into a new wholly-owned subsidiary of iGambit.
The LOI has certain binding and non-binding obligations, including the acquisition consideration which is subject to adjustment and the transaction is subject to various conditions to closing, including satisfactory completion of due diligence, approval of the Company's shareholders, if required, and definitive documentation. A copy of the Form 8-K report may be accessed at www.sec.gov.
David English, CEO of UFCA, states, "UFCA is very excited about partnering with iGambit. Their exceptional leadership, core values of integrity and service to others and strong record of collaboration are a perfect fit for our corporate mission and vision. Our mission is to improve patient outcomes through technological advancement, market innovation, and collaboration, and to provide the best possible service experience to our patients. This partnership will allow us to continue to grow and advance the field of assisted reproductive technology services."
John Salerno, Chairman and CEO of iGambit, said, "We have looked long and hard for companies that can benefit from ownership in the iGambit holding company model and that exhibit exceptional management and significant potential for growth. I am pleased to report that we have found a terrific opportunity for iGambit, UFCA and our stakeholders in this combination. We look forward to having a close and rewarding relationship with the UFCA team as they seek to continue on their mission of providing assisted reproductive technology as an accepted, safe, and practical solution for all in need."
About iGambit Inc: iGambit (OTCBB:IGMB) is a fully reporting publicly-held company. We are a diversified holding company pursuing and evaluating a number of strategic objectives. These objectives include, among others, the potential acquisition of small to medium size businesses. We believe that the background of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner to the companies that we are seeking to acquire. When we acquire a company, we work to assume an active role in the development and growth of the company, providing both strategic guidance and operational support. Once a company joins our partner company network, our collective expertise is leveraged to help position that company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our website does not comprise a part of this press release.
About UFCA: UFCA (www.ufca.us), provides its fertility centers with innovation and thought leadership in assisted reproductive technology. along with administrative services such as finance, accounting, human resources, risk management, legal and purchasing support; marketing and sales support, internet marketing and website support, access to integrated information systems, and access to capital for financing clinic operations and expansion.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this document and elsewhere by iGambit are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes, without limitation, the business outlook, assessment of market conditions, anticipated financial and operating results, strategies, future plans, contingencies and contemplated transactions of the company. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of company operations, or the performance or achievements of the company or industry results, to differ materially from those expressed, or implied by the forward-looking statements. In addition to any such risks, uncertainties and other factors discussed elsewhere herein, risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied for the forward- looking statements include, but are not limited to fluctuations in demand; changes to economic growth in the U.S. and U.S. government policies and regulations, including, but not limited to those affecting the medical fertility clinic industry. iGambit undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in iGambit Inc.'s filings with the Securities and Exchange Commission.
CONTACT: Investor Relations Contact:
iGambit Inc.
John Salerno, CEO
631-670-6777
john@igambit.com
==============================================================
April 3, 2012
iGambit Inc. Reports more than 100% Increase in 2011 Revenue
SMITHTOWN, NY-(Marketwire-April 3, 2012) - iGambit Inc. (OTCBB: IGMB), a diversified technology development and holding company reported results for the year ended December 31, 2011 (in US Dollars).
For 2011, the Company reported revenues of $1,783,904, an annual increase of over 100% from $874,774 in 2010. The increase in revenue was due to revenue generated by our subsidiary Gotham Innovation Labs Inc. (“Gotham”). In addition, we had income from discontinued operations of $247,860 for the year ended December 31, 2011, compared to $1,898,435 for the year ended December 31, 2010. Our net loss was ($383,393) for the year ended December 31, 2011, compared to a net income of $158,137 for the year ended December 31, 2010. The decrease in income from discontinued operations and net income was due to the Digi-Data agreement ending on February 28, 2011.
Management Commentary:
"2011 revenue has shown our investment in our subsidiary Gotham has and continues to meet our expectations. Our year-end financial results promotes further support for Gotham’s business model and we look forward to focusing on additional strategies to foster expansion and continued growth of Gotham” Our operating revenue remains healthy, despite the Dig-Data contingency payment stream from discontinued operations coming to an end. Additionally, we continue to focus on acquisition opportunities to increase our net income and shareholder value.” said John Salerno, President and CEO.
About iGambit Inc.
iGambit, Inc. (IGMB), based in Commack, is a diversified holding company pursuing and evaluating a number of strategic objectives. These objectives include, among others, the potential acquisition of small to medium size businesses. We believe that the background of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner to the companies that we are seeking to acquire. When we acquire a company, we work to assume an active role in the development and growth of the company, providing both strategic guidance and operational support. Once a company joins our partner company network, our collective expertise is leveraged to help position that company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders.
For more information regarding iGambit's financial performance during the year ended December 31, 2011, please refer to the Form 10-K filed with the Securities and Exchange Commission on March 30, 2012 or visit www.igambit.com.
Safe Harbor Statement:
Information contained in this press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements can be identified by the use of forward-looking terminology such as "believes," "expects," "is expected," "intends," "may," "will," "should," "anticipates," "plans" or the negative thereof. These forward-looking statements often include forecasts and projections for future revenue and/or profits and are subject to revision and are not based on audited results. The Company does not undertake to update, revise or correct any forward-looking statements. Investors are cautioned that current results are not necessarily indicative of future results, and actual results may differ from projected amounts. For more complete information concerning factors that could affect the Company's results, reference is made to the Company's registration statements, reports and other documents filed with the Securities and Exchange Commission.
Investor Relations Contact:
ProActive Capital Group LLC.
Jeff Ramson, CEO
646-863-6341
jramson@proactivecapitalgroup.com
==============================================================
November 17, 2011
iGambit Inc. Reports more than 75% Increase in Third Quarter Revenue
HAUPPAUGE, NY-(Marketwire-November 16, 2011) - iGambit Inc. (OTCBB: IGMB), a diversified technology development and holding company reported results for the third quarter ended September 30, 2011 (in US Dollars).
Third quarter revenue increased more than 75% to $410,258 from $232,343 in the same quarter last year. For the nine-month period, revenue increased over 100% to $1,299,602 from $646,002 in the same period last year. The increase in revenue was due to revenue generated by our subsidiary Gotham Innovation Labs Inc. (“Gotham”).
In addition, we had income from discontinued operations of $242,099 for the nine months ended September 30, 2011, compared to $1,537,489 for the nine months ended September 30, 2010, and net loss of $(230,188) for the nine months ended September 30, 2011, compared to net income of $373,668 for the nine months ended September 30, 2010. The decrease in net income was due to the Digi-Data agreement ending on February 28, 2011.
Management Commentary:
"Once again this quarter our investment in our subsidiary Gotham continues to meet our expectations." Our third quarter and year-to-date financial results display the effective combination of Gotham’s thriving business model and the benefits of our support and direction.” We anticipate further growth in Gotham. Our operating revenue remains healthy, despite the Dig-Data contingency payment stream from discontinued operations coming to an end. We continue to focus on acquisition opportunities to increase our net income and shareholder value.” said John Salerno, president and CEO.
About iGambit Inc.
iGambit, Inc. (IGMB), based in Hauppauge, is a diversified holding company pursuing and evaluating a number of strategic objectives. These objectives include, among others, the potential acquisition of small to medium size businesses. We believe that the background of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner to the companies that we are seeking to acquire. When we acquire a company, we work to assume an active role in the development and growth of the company, providing both strategic guidance and operational support. Once a company joins our partner company network, our collective expertise is leveraged to help position that company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders.
For more information regarding iGambit's financial performance during the quarter ended September 30, 2011, please refer to the Form 10-Q filed with the Securities and Exchange Commission on November 10, 2011 or visit www.igambit.com.
Safe Harbor Statement:
Information contained in this press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements can be identified by the use of forward-looking terminology such as "believes," "expects," "is expected," "intends," "may," "will," "should," "anticipates," "plans" or the negative thereof. These forward-looking statements often include forecasts and projections for future revenue and/or profits and are subject to revision and are not based on audited results. The Company does not undertake to update, revise or correct any forward-looking statements. Investors are cautioned that current results are not necessarily indicative of future results, and actual results may differ from projected amounts. For more complete information concerning factors that could affect the Company's results, reference is made to the Company's registration statements, reports and other documents filed with the Securities and Exchange Commission.
Investor Relations Contact:
ProActive Capital Group LLC.
Jeff Ramson, CEO
646-863-6341
jramson@proactivecapitalgroup.com
==============================================================
August 17, 2011
iGambit Inc. Reports 50% Increase in Second Quarter Revenue
HAUPPAUGE, NY-(Marketwire-August 17, 2011) - iGambit Inc. (OTCBB: IGMB), a diversified technology development and holding company reported results for the second quarter ended June 30, 2011 (in US Dollars).
Second quarter revenue increased 52% to $472,441 from $246,317 in the same quarter last year. For the six-month period, revenue increased 47% to $889,344 from $413,659 in the same period last year. The increase in revenue was due to revenue generated by our acquired subsidiary Gotham Innovation Labs Inc. (“Gotham”).
In addition, we had income from discontinued operations of $242,099 for the six months ended June 30, 2011, compared to $1,207,287 for the six months ended June 30, 2010, and net loss of $(76,715) for the six months ended June 30, 2011, compared to net income of $361,024 for the six months ended June 30, 2010. The decrease in net income was due to the Digi-Data agreement ending on February 28, 2011.
Management Commentary:
"Our investment in our subsidiary Gotham continues to exceed all our expectations."Our second quarter and year-to-date financial results reflect both the efficient business model of Gotham and the benefits of our strategic guidance. We anticipate further growth in Gotham. Despite the Dig-Data contingency payment stream from discontinued operations coming to an end, our operating revenue remains healthy, and we continue to focus on acquisition opportunities to increase our net income and shareholder value.” said John Salerno, president and CEO.
About iGambit Inc.
iGambit, Inc. (IGMB), based in Hauppauge, is a diversified holding company pursuing and evaluating a number of strategic objectives. These objectives include, among others, the potential acquisition of small to medium size businesses. We believe that the background of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner to the companies that we are seeking to acquire. When we acquire a company, we work to assume an active role in the development and growth of the company, providing both strategic guidance and operational support. Once a company joins our partner company network, our collective expertise is leveraged to help position that company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders.
For more information regarding iGambit's financial performance during the quarter ended June 30, 2011, please refer to the Form 10-Q filed with the Securities and Exchange Commission on August 15, 2011 or visit www.igambit.com.
Safe Harbor Statement:
Information contained in this press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements can be identified by the use of forward-looking terminology such as "believes," "expects," "is expected," "intends," "may," "will," "should," "anticipates," "plans" or the negative thereof. These forward-looking statements often include forecasts and projections for future revenue and/or profits and are subject to revision and are not based on audited results. The Company does not undertake to update, revise or correct any forward-looking statements. Investors are cautioned that current results are not necessarily indicative of future results, and actual results may differ from projected amounts. For more complete information concerning factors that could affect the Company's results, reference is made to the Company's registration statements, reports and other documents filed with the Securities and Exchange Commission.
Investor Relations Contact:
ProActive Capital Group LLC.
Jeff Ramson, CEO
646-863-6341
jramson@proactivecapitalgroup.com
==============================================================
July 19, 2011
iGambit Inc. Announces DTC Eligibility
DTC Eligibility Improves Efficiency by Moving and Settling Trades Electronically
HAUPPAUGE, NY--(Marketwire-Jul 19, 2011) - iGambit Inc. (OTCBB: IGMB), a diversified technology development and holding company, today announced that the Company has been granted eligibility status by the Depository Trust Company (DTC).
DTC provides clearance, settlement, and information services for equities, corporate and municipal bonds, unit investment trusts, and mortgage-backed securities, money market instruments, and over-the-counter derivatives.
“Becoming DTC eligible will simplify the process by which our shares can be traded or exchanged through brokers of our investors' choice,” stated John Salerno, President and CEO of iGambit. “This is a key milestone for the Company and a major step in increasing our exposure in the investment community.”
About iGambit Inc.
iGambit, Inc. (IGMB), based in Hauppauge, NY, is a technology holding and development company, that focuses on acquiring small to medium size businesses. We believe that the background of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner to the companies that we are seeking to acquire. When we acquire a company, we work to assume an active role in the development and growth of the company, providing both strategic guidance and operational support. We provide strategic guidance to our partner companies relating to, among other things, market positioning, business model and product development, strategic capital expenditures, mergers and acquisitions and exit opportunities. Additionally, we provide operational support to help our partner companies manage day-to-day business and operational issues and implement best practices in the areas of finance, sales and marketing, business development, human resources and legal services. Once a company joins our partner company network, our collective expertise is leveraged to help position that company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders. For more information, please visit www.igambit.com. Information on our website does not comprise a part of this press release.
Safe Harbor Statement:
Information contained in this press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements can be identified by the use of forward-looking terminology such as "believes," "expects," "is expected," "intends," "may," "will," "should," "anticipates," "plans" or the negative thereof. These forward-looking statements often include forecasts and projections for future revenue and/or profits and are subject to revision and are not based on audited results. The Company does not undertake to update, revise or correct any forward-looking statements. Investors are cautioned that current results are not necessarily indicative of future results, and actual results may differ from projected amounts. For more complete information concerning factors that could affect the Company's results, reference is made to the Company's registration statements, reports and other documents filed with the Securities and Exchange Commission.
Investor Relations Contact:
ProActive Capital Group LLC.
Jeff Ramson, CEO
646-863-6341
jramson@proactivecapitalgroup.com
==============================================================
Oct 22, 2009
iGambit Inc. Announces the Acquisition of Gotham Photo Company.
Gotham, a privately owned company based in New York is a leading real estate media and technology provider that, together with Team5, develop web-based software and database tools.
Gotham's core clientele include luxury real estate and hospitality companies that together with Team5's clientele of well-known entertainment and retail brands, insurance, government and medical enterprises encompass a niche market of organizations in need of technology-driven solution. Together, their core technology strengths bring its clients flexibility, user optimization, and cost efficiency with a full suite of graphic and user-experience solutions.
Gotham's marketing and media services provide its clients with high-end photography, building/unit renderings, 2D/3D floor plans, exclusive EXPO Full Screen Media Experience, virtual tours, E-brochures, custom mailing lists and other marketing media tools.
iGambit's acquisition of Gotham / Team5 is in line with its strategy of integrating companies delivering recurring revenue models in targeted vertical industries, such as real estate, where technology is lagging behind the customer. Gotham's services provide great value to its clients, such as real estate brokers, where there is a great need to provide to their clients the attractive marketing solution that bring the greatest result of potential buyers and sellers.
"iGambit and Gotham share the same vision: to create new real estate presentation experiences that build on the convergence of newer technologies. Taking advantage of high end displays, next generation mobile devices and bandwidth, we can do things that -- less than 10 years ago -- required a special effect crew from Industrial Light and Magic." -- John Salerno, CEO of iGambit, Inc.
"By joining a company like iGambit, Gotham has more opportunities to bring to the real estate market the next level of rich and interactive communications experience." -- Vincent Collura, President of Team5 / Gotham Photo Company
* The purchaser of Gotham is Gotham Innovation Lab Inc., a wholly owned subsidiary of the holding company iGambit Inc. based in Hauppauge, New York.
About iGambit Inc.
iGambit, Inc. is a diversified technology development and holding company pursuing and evaluating a number of strategic objectives. These objectives include, among others, the acquisition of other companies and/or the identification of financial or strategic entities who may wish to partner with iGambit.
For more information, please visit www.igambit.com ; www.gothamphotocompany.com and www.team5.com
==============================================================
July 12, 2009
iGAMBIT signs a Letter of Intent (LOI) to acquire the assets of Gotham Photo Company and Team5. Both firms are owned by David Pollack and Vince Collura who upon signing of the definitive agreement, they will join iGAMBIT as part of the management team. Checkout www.team5.com and www.gothamphotocompany.com
$b_rich$ is correct, you should send them an email. They are very responsive.
Long IGMB,
~Magnus
The global wearable medical devices market is expected to surpass $29 billion by 2026, according to a report from Transparency Market Research (TMR), expanding at a projected compound annual growth rate (CAGR) of more than 17% over the next seven years.
https://www.cardiovascularbusiness.com/topics/healthcare-economics/medical-wearables-market-surpass-29b-2026
This is great news for IGMB longs
Long IGMB,
~Magnus
Good Morning, IGMB
Looking forward to a good week and beyond.
Long IGMB,
~Magnus